Literature DB >> 8628338

Brief report: rifampin-resistant tuberculosis in a patient receiving rifabutin prophylaxis.

W R Bishai1, N M Graham, S Harrington, C Page, K Moore-Rice, N Hooper, R E Chaisson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8628338     DOI： 10.1056/NEJM199606133342404

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  4 in total

1.  Management of opportunist mycobacterial infections: Joint Tuberculosis Committee Guidelines 1999. Subcommittee of the Joint Tuberculosis Committee of the British Thoracic Society.

Authors: 
Journal:  Thorax       Date:  2000-03       Impact factor: 9.139

2.  Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations.

Authors:  S L Moghazeh; X Pan; T Arain; C K Stover; J M Musser; B N Kreiswirth
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

3.  Impact of chemorophylaxis policy for AIDS-immunocompromised patients on emergence of bacterial resistance.

Authors:  Ashley A DeNegre; Kellen Myers; Nina H Fefferman
Journal:  PLoS One       Date:  2020-01-30       Impact factor: 3.240

4.  Rifampicin mono-resistance in Mycobacterium tuberculosis in KwaZulu-Natal, South Africa: a significant phenomenon in a high prevalence TB-HIV region.

Authors:  Yacoob Mahomed Coovadia; Sharana Mahomed; Melendhran Pillay; Lise Werner; Koleka Mlisana
Journal:  PLoS One       Date:  2013-11-06       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.